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Different Mechanisms of Calcitonin, Calcitonin Gene-Related Peptide, 
and Somatostatin Regulation by Glucocorticoids in a Cell Culture of 
Human Medullary Thyroid Carcinoma 
Gilbert J. Cote, and Robert F. Gagel* 
We have employed the TT cell line, a model for the human medullary thyroid carcinoma cell, lo study 
the regulation of peptide hormone production by glucocorticoids. Complementary DNA probes were 
used to measure the calcitonin (CT), CT gene-related peptide (CGRP), and somatostatin (SRIF) 
mRNA levels. Dose-response experiments in serum-free medium showed that dexamethasone (six-day 
treatment) lowered somatostatin (to 1% of basal) and CGRP mRNA (to 50% of basal) and stimulated 
CT mRNA (threefold to thirteenfold) with a half-maximal effective concentration of 10 " M. Time 
course studies for cells continuously exposed to 70" M dexamethasone showed a rapid (within hours) 
lowering of SRIF mRNA. whereas the effects on CT and CGRP mRNA required six to eight days. These 
results demonstrate the presence of two mechanisms, transcriptional (somatostatin) and 
posttranscriptional (the RNA splice decision to make CT or CGRP mRNA). that can be hormonally 
regulated. (Henry Ford Hosp MedJ 1987;35:149-52) 
The TT cell line is a continuous cell line originally derived from the needle biopsy of a human medullary thyroid car-
cinoma (1). We have employed this cell line to study the produc-
tion of the peptide hormones calcitonin (CT), CT gene-related 
peptide (CGRP), and somatostatin (SRIF), Two precursor pep-
tides for CT and CGRP are produced from the CT gene by alter-
native RNA processing, whereas the SRIF gene codes for the 
production of a single precursor peptide (2,3). Because the TT 
cell line produces all three of these peptides in significant quan-
tities, it provides a useful model system for studying the regula-
tion ofthe two genes. We have previously demonstrated an 
effect of the synthetic glucocorticoid dexamethasone on 
production of SRIF (4), as well as CT and CGRP (5). In this pa-
per we present and compare the effects of dexamethasone treat-
ment on CT, CGRP and SRIF mRNA in the TT cell line. The 
results demonstrate the existence of two distinct mechanisms of 
action for dexamethasone: a rapid transcriptional effect seen on 
SRIF, and a more slowly developing posttranscriptional effect 
on the processing of primary RNA transcript derived from the 
CT gene. 
Experimental Procedures 
Cell culture methodology 
The TT cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal calf semm (Gibco Laboratories, Grand 
Island, NY), using previously described techniques (6). In 
experiments using semm-free medium, cells were subcultured 
48 hours before treatment in serum-containing medium and 
then switched to semm-free medium 24 hours before the onset 
of treatment. Serum-free defined medium was prepared as 
previously described for a rat C-cell line (7), Cell counts were 
determined with the aid of a Coulter Counter (model ZF), as pre-
viously described (6). All steroids were added to the medium as 
25 mM stocks prepared in ethanol. Control cells received an 
equal volume of ethanol. 
Preparation of RNA 
The TT cells were plated at an initial density of ~3 x 10*" 
cells/100 mm dish. The cells were allowed to attach for 24 hours 
before treatment. Total cellular RNA was isolated from various 
cell types by the guanidine isothiocyanate procedure (8), with 
the previously described modifications (5). Total RNA was 
stored dissolved in sterile distilled H^O in the presence of 
vanadium-riboside complex (9) at -70°C. 
Hybridizations 
RNA dot blot hybridizations were performed by immobiliza-
tion of purified total RNA onto nitrocellulose paper as described 
by Thomas (10). The SRIF-, CT-, and CGRP-specific probes 
were prepared as previously described (4,5). Prehybridization, 
hybridization, and washing procedures were identical to those of 
Thomas (10). Autoradiographs were quantitated by computer-
assisted densitometric scanning with a video camera as de-
scribed by Mariash et al (11). 
Results 
Fig 1 shows the effect of a pharmacologic dose of dexa-
methasone (10-* M) on CT, CGRP, and SRIF mRNA levels. 
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Fig 1—Time course of dexamethasone treatment on CT. CGRP. 
and SRIF mRNA production in the TT cells. The TT cells were 
plated at an initial density of ~3 X 70* cells/100 mm dish and 
allowed to attach in growth medium (24 hours) before changing 
to medium containing I x 70 * M dexamethasone. Medium 
was changed at 48-hour intervals. RNA measurements were 
made at indicated time points after the initiation of treatment by 
removal of medium and addition of guanidine isothiocyanate. 
The values represent the average hybridization value of two 
dishes as determined by dot hybridization and quantitated by a 
computer-assisted densitometer. 
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Fig 2—Dose-response curve for the effect of dexamethasone on 
CT. CGRP, and SRIF mRNA production. The TT cells were 
plated at an initial density of ~3 X ICP cells/100 mm dish in 
serum-containing medium for 24 hours, then switched to serum-
free medium for 24 hours before treatment. Cells were then 
grown in the presence of the indicated concentration of dexa-
methasone in serum-free medium for six days with medium 
changed at 48-hour intervals. The mRNA levels were deter-
mined as described in Fig 1. 
Dexamethasone treatment affected the levels of each mRNA dif-
ferently. The levels of SRIF mRNA showed a rapid decrease 
(levels reach 50% of control by 12 hours) and were barely detect-
able by 48 hours. While CGRP mRNA levels also declined as a 
result of dexamethasone treatment, a six-day treatment was re-
quired to achieve a 50% reduction. Unlike SRIF and CGRP, CT 
mRNA showed an increase over two to eight days following 
treatment with dexamethasone. Although this increase could be 
explained by an enhancement of transcription, the rate ofthe re-
sponse and the simultaneous decrease in CGRP mRNA levels 
suggest a more complex explanation. 
To determine whether glucocorticoids might play a physio-
logically significant role in the regulation of these genes, we ex-
amined the dose-dependent effects of dexamethasone on CT, 
CGRP and SRIF mRNA levels (Fig 2). Again, both SRIF and 
CGRP mRNA levels were depressed, while CT levels were 
enhanced. The TT cells are typically grown in the presence of 
10% fetal bovine serum, which we have found to contain ap-
proximately 10 M endogenous steroid. For this reason, the 
dose-response curves were generated in serum-free medium. 
The half-maximal doses of dexamethasone (10' M for CT, 10'* 
M for CGRP, and 10" M for SRIF mRNA) are shifted 
two orders of magnitude to the left, compared to our previous 
findings in the presence of serum (4,5), and now approach phys-
iologically significant levels (12). 
Discussion 
Differences between regulation ofthe CT and SRIF genes 
The results presented in this and previous papers (4,5) sug-
gest that dexamethasone acts to regulate mRNA levels by several 
mechanisms in the human medullary thyroid carcinoma TT cell 
line. Three possible points of regulation are transcription, RNA 
processing, and mRNA degradation. Fig 3 schematically dem-
onstrates the production of CT, CGRP and SRIF mRNA from 
their respective genes. The SRIF gene is transcribed, the tran-
script undergoes RNA processing in the nucleus to produce ma-
ture mRNA, and then the mRNA is typically degraded in the 
cytoplasm after several rounds of translation. Unlike the SRIF 
gene, the CT gene's primary transcript is altematively processed 
to produce one of two possible mRNAs, one coding for CT and 
the other for CGRP Therefore, RNA processing becomes a key 
regulatory step in the production of CT and CGRP mRNA, 
Effect of dexamethasone on SRIF mRNA levels 
We have shown that dexamethasone rapidly lowered SRIF 
mRNA levels. Because the ~ 12-hour half-life of the SRIF 
mRNA (data not shown) approximates the rate of decline in 
SRIF mRNA following dexamethasone treatment, we favor a 
model whereby dexamethasone acts to inhibit directiy the tran-
scription ofthe SRIF gene. The possibility that dexamethasone 
affects SRIF mRNA stability, though unlikely, has not been 
excluded. 
Effect of dexamethasone on CT and CGRP mRNA levels 
Dexamethasone acts to enhance CT mRNA levels and de-
crease CGRP mRNA levels. Regulation of this event must occur 
at either the RNA processing step or at the level of mRNA deg-
radation. Transcriptional regulation alone would result in par-
allel changes in CT and CGRP mRNA levels, such as seen after 
phorbol ester or cAMP analog treatment (12), and not the diver-
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Fig 3—Schematic outline comparing RNA processing of the pri-
mary transcript from the SRIF gene and the CT gene: A) pro-
cessing ofthe SRIF gene primary transcript to SRIF mRNA, and 
B) processing of the CT gene primary transcript into CT and 
CGRP mRNA. 
gence seen here. We have previously demonstrated that dexa-
methasone has no effect on the half-life of either CT or CGRP 
mRNA (5). Therefore, we proposed that dexamethasone must 
be acting to affect the RNA processing of the primary transcript. 
How might dexamethasone alter the RNA processing of the 
primary transcript of the CT gene? The first possibility to con-
sider is a direct effect of dexamethasone on RNA processing. 
The dexamethasone-glucocorticoid receptor complex, or some 
other dexamethasone-binding protein with regulatory abilities, 
might affect RNA processing directly. Glucocorticoid receptors 
have been demonstrated to bind RNA (13), and RNA processing 
is brought about by protein-RNA complexes (14). However, it is 
unlikely that dexamethasone is acting through one of these di-
rect mechanisms, because the time course for the effect is too 
slow, and a similar effect can be produced in the absence of any 
steroids by long-term culturing of the cells without subculturing 
(as described by A. deBustros et al at these proceedings). There-
fore, we propose that dexamethasone is acting in an indirect 
fashion to alter RNA processing. 
Model for the regulation of alternative RNA processing 
by dexamethasone 
To explain the regulation of the altemative processing of the 
CT gene primary transcript, we favor a model where the produc-
tion of CT mRNA is the unregulated pathway or "null" choice, 
and production of CGRP mRNA requires the presence of spe-
cific factor(s). This model is based on the available information 
regarding the processing of the CT gene transcript (15) and on 
current theories of RNA processing (14). From this model we 
predict that in the thyroid C-cell, cleavage and polyadenylation 
at the site immediately following the CT exon are the early steps 
which necessitate an exon 3 to CT exon splice (Fig 3). If our CT 
"null" choice is correct, then the production of CGRP mRNA 
would require that: 1) polyadenylation immediately after the CT 
exon be blocked; and 2) because the blockage of cleavage fol-
lowing the CT exon would be insufficient to ensure CGRP 
mRNA production, a mechanism must exist to prevent an exon 3 
to CT exon splice. This is most easily accomplished either by 
preventing branch point formation within the third intron or 
by blocking the accessibility of the 3' splice junction (studies 
have shown that spliceosome binding to the 3' splice site is re-
quired for 5' cleavage) (14). This blockage would then allow 
preferential usage of the next available 3' splice junction (at the 
CGRP exon). 
This model would predict the existence of protein or RNA 
factor(s) in CGRP-producing cell types functioning to block 
polyadenylation immediately after the CT exon and removal of 
the intron immediately before the CT exon. Whether this is ac-
complished by a single factor, several factors, or a complex re-
mains to be elucidated. One such way in which the interaction 
could occur is diagramed in Fig 4, where separate binding sites 
cause the RNA to loop out while forcing CGRP mRNA pro-
duction. If the production of this complex was inhibited by 
dexamethasone, cell cycle-dependent or cell type-dependent 
mechanisms, then the production of CT would be favored. 
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